These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16867042)

  • 21. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Chung CH
    Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Status of biological agent therapy in inflammatory bowel disease].
    Qian JM; Tang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Apr; 16(4):311-4. PubMed ID: 23608788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.
    Khan DA
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):115-20. PubMed ID: 27499538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scientific and regulatory considerations on the immunogenicity of biologics.
    Shankar G; Shores E; Wagner C; Mire-Sluis A
    Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
    Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A
    J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse Reactions to Biologic Therapy.
    Patel SV; Khan DA
    Immunol Allergy Clin North Am; 2017 May; 37(2):397-412. PubMed ID: 28366484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity as a result of immunostimulation by biologics.
    Gribble EJ; Sivakumar PV; Ponce RA; Hughes SD
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):209-34. PubMed ID: 17428152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric psoriasis: updates in biologic therapies.
    Sukhatme SV; Gottlieb AB
    Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A composite report on the adverse reactions of drugs (author's transl)].
    Zhonghua Nei Ke Za Zhi; 1979; 18(2):128-31. PubMed ID: 555902
    [No Abstract]   [Full Text] [Related]  

  • 32. [Types of drug side effects and their classification].
    Davydov VF
    Farmakol Toksikol; 1980; 43(6):652-61. PubMed ID: 7450000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity/hypersensitivity of biologics.
    Leach MW; Rottman JB; Hock MB; Finco D; Rojko JL; Beyer JC
    Toxicol Pathol; 2014 Jan; 42(1):293-300. PubMed ID: 24240973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Introduction.
    Gottlieb AB
    Dermatol Ther; 2009; 22(1):1. PubMed ID: 19222512
    [No Abstract]   [Full Text] [Related]  

  • 37. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms.
    Myers JS
    Oncol Nurs Forum; 2008 Sep; 35(5):802-7. PubMed ID: 18765326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy.
    Quatan N; Meyer B; Bailey M; Pandha H
    Prostate Cancer Prostatic Dis; 2006; 9(4):420-5. PubMed ID: 16983395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes.
    Ryden A; Stechova K; Durilova M; Faresjö M
    Diabetes Metab Res Rev; 2009 May; 25(4):335-43. PubMed ID: 19382103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches.
    Prandota J
    Am J Ther; 2007; 14(1):63-105. PubMed ID: 17303977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.